InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,264.40
(
0.00%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.77
(
0.41%
)
Bitcoin
61,289.06
(
-0.52%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ghmm

Send PM Follow Ignore
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

ghmm

Re: biomaven0 post# 187195

Saturday, 02/07/2015 9:04:05 PM

Saturday, February 07, 2015 9:04:05 PM

Post# of 252412
GILD acquisitions:

They bought Myogen mainly for their PAH drug (Ambrisentan) and a hypertension drug that would later get dropped (I think it failed in Phase 3).

I haven't followed Gilead as close as others so I may be off here. It just seems to me they like to buy pre-commercial assets. Even though they have a big buyback and now a dividend I don't see why they wouldn't take advantage of rates to issue some long term debt if the right deal(s) came along.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up